Lifecore Biomedical to Participate at DCAT Week 2026
Lifecore Biomedical (NASDAQ: LFCR) will participate in DCAT Week 2026, March 23-26, 2026, in New York City.
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR) will participate in DCAT Week 2026, March 23-26, 2026, in New York City. Lifecore's team will host customers and prospective partners to discuss development and manufacturing solutions for injectable programs. Meetings are available by contacting cdmo@lifecore.com.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LFCR
On Feb 17, the day this news came out, LFCR closed 1.13% above the previous close.
Data tracked by StockTitan Argus for the Feb 17 session.
Key Figures
- Q3 2025 revenue
- $31,109 thousand
- Total revenues for quarter ended September 30, 2025
- Prior-year revenue
- $24,705 thousand
- Total revenues prior comparable period
- Q3 2025 gross profit
- $7,791 thousand
- Quarter ended September 30, 2025
- Q3 2025 operating loss
- $3,067 thousand
- Improved from $11,584 thousand prior period
- Q3 2025 net loss
- $9,991 thousand
- Quarter ended September 30, 2025
- Cash & equivalents
- $18,856 thousand
- Balance as of September 30, 2025
- Related party term loan
- $179,562 thousand
- Principal with effective interest rate of 20.9%
- Equity deficit
- $10,537 thousand
- Stockholders’ equity deficit as of Q3 2025
Historical Context
-
Announced RSU and option grants to two newly hired employees.
-
Planned addition to the Nasdaq Biotechnology Index (NBI).
-
Signed CDMO master services deal with large multinational pharma partner.
-
Planned participation in the 44th Annual J.P. Morgan Healthcare Conference.
-
Announced participation in Jefferies and Stephens investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cdmo technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at DCAT Week 2026. The conference will take place March 23-26, 2026, in New York City.
Details regarding Lifecore’s participation are as follows:
- DCAT Week 2026
Details: Lifecore team will host customers and prospective partners to discuss development and manufacturing solutions for existing and new injectable programs.
Conference Dates: March 23-26, 2026
Location: New York, NY
If you are interested in meeting with Lifecore during DCAT week, please reach out to us at: cdmo@lifecore.com.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) 415-675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.